[
  {
    "ts": "2025-06-27T13:19:09+00:00",
    "headline": "Vertex Pharmaceuticals Incorporated (VRTX) Benefited from the Launch of its New Drug",
    "summary": "Parnassus Investments, an investment management company, released the “Parnassus Growth Equity Fund” first quarter 2025 investor letter. A copy of the letter can be downloaded here. In the first quarter, the Fund (Investor Shares) returned -8.59% (net of fees), outperforming the Russell 1000 Growth Index’s -9.97% decline. In the first quarter, post-election optimism, driven by […]",
    "url": "https://finance.yahoo.com/news/vertex-pharmaceuticals-incorporated-vrtx-benefited-131909416.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "39e40525-7b64-3504-ad88-f1a517aca062",
      "content": {
        "id": "39e40525-7b64-3504-ad88-f1a517aca062",
        "contentType": "STORY",
        "title": "Vertex Pharmaceuticals Incorporated (VRTX) Benefited from the Launch of its New Drug",
        "description": "",
        "summary": "Parnassus Investments, an investment management company, released the “Parnassus Growth Equity Fund” first quarter 2025 investor letter. A copy of the letter can be downloaded here. In the first quarter, the Fund (Investor Shares) returned -8.59% (net of fees), outperforming the Russell 1000 Growth Index’s -9.97% decline. In the first quarter, post-election optimism, driven by […]",
        "pubDate": "2025-06-27T13:19:09Z",
        "displayTime": "2025-06-27T13:19:09Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/d61abed3f7567688cd16b4e2785171ec",
          "originalWidth": 768,
          "originalHeight": 430,
          "caption": "Is Vertex Pharmaceuticals Incorporated (VRTX) the Best Stock to Buy According to Jim Simons’ Renaissance Technologies?",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/73o67FZt31QGX4RW9oCwEA--~B/aD00MzA7dz03Njg7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/d61abed3f7567688cd16b4e2785171ec.cf.webp",
              "width": 768,
              "height": 430,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/eKC281F2zJCXGmB_sO5saA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/d61abed3f7567688cd16b4e2785171ec.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/vertex-pharmaceuticals-incorporated-vrtx-benefited-131909416.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/vertex-pharmaceuticals-incorporated-vrtx-benefited-131909416.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "VRTX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]